A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy (IMRT)
Primary Purpose
Head and Neck Cancer
Status
Terminated
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
IMRT
Sponsored by
About this trial
This is an interventional treatment trial for Head and Neck Cancer focused on measuring Newly Diagnosed head and neck cancer
Eligibility Criteria
Inclusion Criteria:
- Age >= 18
- Karnofsky Performance Status of >= 60
- New diagnosis of head-and-neck cancer, all subsites included (i.e. nasopharynx, oropharynx, oral cavity, hypopharynx, larynx.)
- All stages with measurable gross disease (>= 1.0 cm) by CT imaging
- Pathologic confirmation of squamous cell carcinoma by biopsy or cytology
- Signed study-specific consent form
- Sequential or concurrent chemotherapy is allowed but not mandated. (no chemotherapy is allowed if patient is judged not to be a candidate for chemotherapy by the medical oncologist)
Exclusion Criteria
- Age < 18
- Karnofsky Performance Status < 60
- Radiographic or pathologic evidence of distant metastatic disease (i.e. other than cervical lymph nodes)
- Prior radiation therapy to the head-and-neck region
Sites / Locations
- Washington University School of Medicine
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
IMRT
Arm Description
External beam radiation with 6 MV photons will be delivered in 200 cGy daily fractions, 35 fractions over 7 weeks for a total dose of 7000 cGy.
Outcomes
Primary Outcome Measures
Feasibility of adaptive radiation therapy in the definitive treatment (MLC-based IMRT or helical tomotherapy)
Feasibility is determined by employing weekly 3D onboard imaging for plan re-evaluation and initiation of an adaptive process if the original PTV and/or normal structure goals are compromised.
Secondary Outcome Measures
Measure additional time required by physician and ancillary staff for the process of adaptive IMRT
Recording on a weekly basis the actual time required for repeat CT imaging, plan re-evaluation, replanning, and repeat physics QA.
Identify a subset of patients in whom adaptive IMRT would be recommended
Measure acute and late toxicity
Local, regional, and distant recurrence
Full Information
NCT ID
NCT00608751
First Posted
January 2, 2008
Last Updated
May 22, 2013
Sponsor
Washington University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT00608751
Brief Title
A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy
Acronym
IMRT
Official Title
A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy in the Definitive Treatment of Head-and-Neck Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
May 2013
Overall Recruitment Status
Terminated
Why Stopped
Lack of accrual and software issues
Study Start Date
January 2007 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients with head and neck cancer and are schedule to receive standard radiation therapy known as IMRT to treat cancer
Detailed Description
In this study, we will plan additional measurements of the position of the patient's organs weekly during radiation treatment. We will analyze these measurements in order to evaluate whether we need to adjust our treatment procedures for the remainder of the treatments. We might adjust the dose of radiation received to specific organs in order to try to minimize the amount of radiation the healthy tissue receives.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Cancer
Keywords
Newly Diagnosed head and neck cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IMRT
Arm Type
Experimental
Arm Description
External beam radiation with 6 MV photons will be delivered in 200 cGy daily fractions, 35 fractions over 7 weeks for a total dose of 7000 cGy.
Intervention Type
Radiation
Intervention Name(s)
IMRT
Primary Outcome Measure Information:
Title
Feasibility of adaptive radiation therapy in the definitive treatment (MLC-based IMRT or helical tomotherapy)
Description
Feasibility is determined by employing weekly 3D onboard imaging for plan re-evaluation and initiation of an adaptive process if the original PTV and/or normal structure goals are compromised.
Time Frame
7 weeks
Secondary Outcome Measure Information:
Title
Measure additional time required by physician and ancillary staff for the process of adaptive IMRT
Description
Recording on a weekly basis the actual time required for repeat CT imaging, plan re-evaluation, replanning, and repeat physics QA.
Time Frame
7 weeks
Title
Identify a subset of patients in whom adaptive IMRT would be recommended
Time Frame
7 weeks
Title
Measure acute and late toxicity
Time Frame
Until patient death
Title
Local, regional, and distant recurrence
Time Frame
Until recurrence
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age >= 18
Karnofsky Performance Status of >= 60
New diagnosis of head-and-neck cancer, all subsites included (i.e. nasopharynx, oropharynx, oral cavity, hypopharynx, larynx.)
All stages with measurable gross disease (>= 1.0 cm) by CT imaging
Pathologic confirmation of squamous cell carcinoma by biopsy or cytology
Signed study-specific consent form
Sequential or concurrent chemotherapy is allowed but not mandated. (no chemotherapy is allowed if patient is judged not to be a candidate for chemotherapy by the medical oncologist)
Exclusion Criteria
Age < 18
Karnofsky Performance Status < 60
Radiographic or pathologic evidence of distant metastatic disease (i.e. other than cervical lymph nodes)
Prior radiation therapy to the head-and-neck region
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wade Thorstad, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University School of Medicine
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
12. IPD Sharing Statement
Links:
URL
http://www.siteman.wustl.edu
Description
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Learn more about this trial
A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy
We'll reach out to this number within 24 hrs